Stockreport

Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

Kymera Therapeutics, Inc.  (KYMR) 
PDF KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively FDA gra [Read more]